EP 301Alternative Names: EP-301
Latest Information Update: 12 Oct 2016
At a glance
- Originator EpiThany; University of Washington
- Class Antigens; Vaccines
- Mechanism of Action Th1 cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 05 Oct 2016 Phase-I clinical trials in Breast cancer in USA (Parenteral) (EpiThany pipeline, October 2016)